Jump to content

Lurbinectedin: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
correct pronunciation
consistent citation formatting
Line 110: Line 110:
Lurbinectedin is [[indicated]] for the treatment of adults with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.<ref name="FDA Zepzelca announcement" />
Lurbinectedin is [[indicated]] for the treatment of adults with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.<ref name="FDA Zepzelca announcement" />


==Structure==
== Structure ==
Lurbinectedin is structurally similar to [[trabectedin]], although the tetrahydroisoquinoline present in trabectedin is replaced with a tetrahydro β-carboline which enables lurbinectedin to exhibit increased antitumor activity compared with trabectedin.<ref>{{cite journal | vauthors = Takahashi R, Mabuchi S, Kawano M, Sasano T, Matsumoto Y, Kuroda H, Kozasa K, Hashimoto K, Sawada K, Kimura T | display-authors=6 |title=Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary |journal=PLOS ONE |date=March 2016 |volume=11 |issue=3 |pages=e0151050 |doi=10.1371/journal.pone.0151050 |pmid=26986199 |pmc=4795692 |bibcode=2016PLoSO..1151050T |doi-access=free | name-list-style=vanc }}</ref>
Lurbinectedin is structurally similar to [[trabectedin]], although the tetrahydroisoquinoline present in trabectedin is replaced with a tetrahydro β-carboline which enables lurbinectedin to exhibit increased antitumor activity compared with trabectedin.<ref>{{cite journal | vauthors = Takahashi R, Mabuchi S, Kawano M, Sasano T, Matsumoto Y, Kuroda H, Kozasa K, Hashimoto K, Sawada K, Kimura T | display-authors = 6 | title = Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary | journal = PloS One | volume = 11 | issue = 3 | pages = e0151050 | date = March 2016 | pmid = 26986199 | pmc = 4795692 | doi = 10.1371/journal.pone.0151050 | doi-access = free | bibcode = 2016PLoSO..1151050T }}</ref>


==Synthesis==
==Synthesis==
Synthesis of lurbinectedin starts from small, common starting materials that require twenty-six individual steps to produce the drug with overall yield of 1.6%.<ref>{{cite journal | vauthors = He W, Zhang Z, Ma D | title = A Scalable Total Synthesis of the Antitumor Agents Et-743 and Lurbinectedin | journal = Angew Chem Int Ed Engl | volume = 58 | issue = 12 | pages = 3972–3975 | date = March 2019 | pmid = 30689274 | doi = 10.1002/anie.201900035 | s2cid = 59306678 }}</ref>
Synthesis of lurbinectedin starts from small, common starting materials that require twenty-six individual steps to produce the drug with overall yield of 1.6%.<ref>{{cite journal | vauthors = He W, Zhang Z, Ma D | title = A Scalable Total Synthesis of the Antitumor Agents Et-743 and Lurbinectedin | journal = Angewandte Chemie | volume = 58 | issue = 12 | pages = 3972–3975 | date = March 2019 | pmid = 30689274 | doi = 10.1002/anie.201900035 | s2cid = 59306678 }}</ref>


==Mechanism of action==
==Mechanism of action==
According to PharmaMar,<ref>PharmaMar presentation of Lurbinectedin's Mechanism of Action Lurbinectedin {{sic|nolink=y|reason=error in source|Mechanisim}} of Action | https://www.youtube.com/watch?v=8daELhxAXcQ {{Webarchive|url=https://web.archive.org/web/20201118071307/https://www.youtube.com/watch?v=8daELhxAXcQ |date=18 November 2020 }}</ref> lurbinectedin inhibits the active [[Transcription (biology)|transcription]] of the encoding genes. This has two consequences. It promotes [[tumor]] cell death and normalizes the tumor microenvironment. Active transcription is the process by which there are specific signal where information contained in the [[DNA]] sequence is transferred to an [[RNA]] molecule. This activity depends on the activity of an enzyme called [[RNA polymerase II]]. Lurbinectedin inhibits transcription through a very precise mechanism. Firstly, lurbinectedin binds to specific DNA sequences. It is at these precise spots that slides down the DNA to produce RNA polymerase II that is blocked and degraded by lurbinectedin. Lurbinectedin also has important role in tumor microenvironment. The tumor cells act upon [[macrophages]] to avoid them from behaving like an activator of the [[immune system]]. Macrophages can contribute to tumor growth and progression by promoting tumor cell proliferation and invasion, fostering tumor angiogenesis and suppressing antitumor immune cells.<ref>{{cite journal | vauthors = Qian BZ, Pollard JW | title = Macrophage diversity enhances tumor progression and metastasis | journal = Cell | volume = 141 | issue = 1 | pages = 39–51 | date = April 2010 | pmid = 20371344 | pmc = 4994190 | doi = 10.1016/j.cell.2010.03.014 }}</ref><ref name="nature.com">{{cite journal | vauthors = Engblom C, Pfirschke C, Pittet MJ | title = The role of myeloid cells in cancer therapies | journal = Nature Reviews. Cancer | volume = 16 | issue = 7 | pages = 447–62 | date = July 2016 | pmid = 27339708 | doi = 10.1038/nrc.2016.54 | s2cid = 21924175 }}</ref> Attracted to oxygen-starved ([[hypoxia (medical)|hypoxic]]) and necrotic tumor cells they promote [[chronic inflammation]]. So, not only that macrophages inhibit immune system avoiding the destruction of tumor cells, but they also create tumor tissue that allows tumor growth. However, macrophages associated with tumors are cells that are addicted to the transcription process. Lurbinectedin acts specifically on the macrophages associated with tumors in two ways: firstly, by inhibiting the transcription of macrophages that leads to cell death and secondly, inhibiting the production of tumor growth factors. In this way, lurbinectedin normalizes the tumor microenvironment.
According to PharmaMar,<ref>PharmaMar presentation of Lurbinectedin's Mechanism of Action Lurbinectedin {{sic|nolink=y|reason=error in source|Mechanisim}} of Action | https://www.youtube.com/watch?v=8daELhxAXcQ {{Webarchive|url=https://web.archive.org/web/20201118071307/https://www.youtube.com/watch?v=8daELhxAXcQ |date=18 November 2020 }}</ref> lurbinectedin inhibits the active [[Transcription (biology)|transcription]] of the encoding genes. This has two consequences. It promotes [[tumor]] cell death and normalizes the tumor microenvironment. Active transcription is the process by which there are specific signal where information contained in the [[DNA]] sequence is transferred to an [[RNA]] molecule. This activity depends on the activity of an enzyme called [[RNA polymerase II]]. Lurbinectedin inhibits transcription through a very precise mechanism. Firstly, lurbinectedin binds to specific DNA sequences. It is at these precise spots that slides down the DNA to produce RNA polymerase II that is blocked and degraded by lurbinectedin. Lurbinectedin also has important role in tumor microenvironment. The tumor cells act upon [[macrophages]] to avoid them from behaving like an activator of the [[immune system]]. Macrophages can contribute to tumor growth and progression by promoting tumor cell proliferation and invasion, fostering tumor angiogenesis and suppressing antitumor immune cells.<ref>{{cite journal | vauthors = Qian BZ, Pollard JW | title = Macrophage diversity enhances tumor progression and metastasis | journal = Cell | volume = 141 | issue = 1 | pages = 39–51 | date = April 2010 | pmid = 20371344 | pmc = 4994190 | doi = 10.1016/j.cell.2010.03.014 }}</ref><ref name="nature.com">{{cite journal | vauthors = Engblom C, Pfirschke C, Pittet MJ | title = The role of myeloid cells in cancer therapies | journal = Nature Reviews. Cancer | volume = 16 | issue = 7 | pages = 447–462 | date = July 2016 | pmid = 27339708 | doi = 10.1038/nrc.2016.54 | s2cid = 21924175 }}</ref> Attracted to oxygen-starved ([[hypoxia (medical)|hypoxic]]) and necrotic tumor cells they promote [[chronic inflammation]]. So, not only that macrophages inhibit immune system avoiding the destruction of tumor cells, but they also create tumor tissue that allows tumor growth. However, macrophages associated with tumors are cells that are addicted to the transcription process. Lurbinectedin acts specifically on the macrophages associated with tumors in two ways: firstly, by inhibiting the transcription of macrophages that leads to cell death and secondly, inhibiting the production of tumor growth factors. In this way, lurbinectedin normalizes the tumor microenvironment.


== History ==
== History ==
Line 129: Line 129:
===Clinical Trials===
===Clinical Trials===
Lurbinectedin can be used as monotherapy in the treatment of SCLC.{{medcn|date=June 2020}} Lurbinectedin monotherapy demonstrated the following clinical results in relapsed extensive stage SCLC:
Lurbinectedin can be used as monotherapy in the treatment of SCLC.{{medcn|date=June 2020}} Lurbinectedin monotherapy demonstrated the following clinical results in relapsed extensive stage SCLC:
:* For sensitive disease (chemotherapy-free interval of ≥ 90 days) overall response rate (ORR) was 46.6% with 79.3% disease control rate and median overall survival (OS) being increased to 15.2 months.<ref name="Efficacy and safety profile of lurb">{{cite journal |last1=Paz-Ares |first1=Luis G. |last2=Trigo Perez |first2=Jose Manuel |last3=Besse |first3=Benjamin |last4=Moreno |first4=Victor |last5=Lopez |first5=Rafael |last6=Sala |first6=Maria Angeles |last7=Ponce Aix |first7=Santiago |last8=Fernandez |first8=Cristian Marcelo |last9=Siguero |first9=Mariano |last10=Kahatt |first10=Carmen Maria |last11=Zeaiter |first11=Ali Hassan |last12=Zaman |first12=Khalil |last13=Boni |first13=Valentina |last14=Arrondeau |first14=Jennifer |last15=Martinez Aguillo |first15=Maite |last16=Delord |first16=Jean-Pierre |last17=Awada |first17=Ahmad |last18=Kristeleit |first18=Rebecca Sophie |last19=Olmedo Garcia |first19=Maria Eugenia |last20=Subbiah |first20=Vivek | display-authors = 6 |title=Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial |journal=Journal of Clinical Oncology |date=May 2019 |volume=37 |issue=15_suppl |pages=8506 |doi=10.1200/JCO.2019.37.15_suppl.8506 |s2cid=190884224 | name-list-style=vanc }}</ref>
:* For sensitive disease (chemotherapy-free interval of ≥ 90 days) overall response rate (ORR) was 46.6% with 79.3% disease control rate and median overall survival (OS) being increased to 15.2 months.<ref name="Efficacy and safety profile of lurb">{{cite journal | vauthors = Paz-Ares LG, Trigo Perez JM, Besse B, Moreno V, Lopez R, Sala MA, Ponce Aix S, Fernandez CM, Siguero M, Kahatt CM, Zeaiter AH, Zaman K, Boni V, Arrondeau J, Martinez Aguillo M, Delord J, Awada A, Kristeleit RS, Olmedo Garcia ME, Subbiah V | display-authors = 6 |title=Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial |journal=Journal of Clinical Oncology |date=May 2019 |volume=37 |issue=15_suppl |pages=8506 |doi=10.1200/JCO.2019.37.15_suppl.8506 |s2cid=190884224 }}</ref>
:* For resistant disease (chemotherapy-free interval of < 90 days) overall response rate (ORR) was 21.3% with 46.8% disease control rate and 5.1 months median overall survival (OS).<ref name="Efficacy and safety profile of lurb"/>
:* For resistant disease (chemotherapy-free interval of < 90 days) overall response rate (ORR) was 21.3% with 46.8% disease control rate and 5.1 months median overall survival (OS).<ref name="Efficacy and safety profile of lurb"/>


Lurbinectedin is also being investigated in combination with [[doxorubicin]] as second-line therapy in a randomized Phase III trial.{{medcn|date=June 2020}} While overall survival in this trial is not yet known, response rates at second line were
Lurbinectedin is also being investigated in combination with [[doxorubicin]] as second-line therapy in a randomized Phase III trial.{{medcn|date=June 2020}} While overall survival in this trial is not yet known, response rates at second line were
:* 91.7% in sensitive disease with median progression-free survival of 5.8 months, and
:* 91.7% in sensitive disease with median progression-free survival of 5.8 months, and
:* 33.3% in resistant disease with median progression-free of 3.5 months.<ref name=pmid28961837>{{cite journal |last1=Calvo |first1=E. |last2=Moreno |first2=V. |last3=Flynn |first3=M. |last4=Holgado |first4=E. |last5=Olmedo |first5=M.E. |last6=Lopez Criado |first6=M.P. |last7=Kahatt |first7=C. |last8=Lopez-Vilariño |first8=J.A. |last9=Siguero |first9=M. |last10=Fernandez-Teruel |first10=C. |last11=Cullell-Young |first11=M. |last12=Soto Matos-Pita |first12=A. |last13=Forster |first13=M. | display-authors =6 |title=Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study |journal=Annals of Oncology |date=October 2017 |volume=28 |issue=10 |pages=2559–2566 |doi=10.1093/annonc/mdx357 |pmid=28961837 |pmc=5834091 | name-list-style=vanc }}</ref><ref>{{cite press release | title=PharmaMar and Bionical Emas Launch Expanded Access Program for Lurbinectedin in Relapsed Small Cell Lung Cancer in the U.S. | publisher=Bionical Emas | via=PR Newswire | date=27 January 2020 | url=https://www.prnewswire.com/news-releases/pharmamar-and-bionical-emas-launch-expanded-access-program-for-lurbinectedin-in-relapsed-small-cell-lung-cancer-in-the-us-300993470.html | access-date=4 May 2022 | archive-date=18 August 2022 | archive-url=https://web.archive.org/web/20220818204932/https://www.prnewswire.com/news-releases/pharmamar-and-bionical-emas-launch-expanded-access-program-for-lurbinectedin-in-relapsed-small-cell-lung-cancer-in-the-us-300993470.html | url-status=live }}</ref>
:* 33.3% in resistant disease with median progression-free of 3.5 months.<ref name=pmid28961837>{{cite journal | vauthors = Calvo E, Moreno V, Flynn M, Holgado E, Olmedo ME, Lopez Criado MP, Kahatt C, Lopez-Vilariño JA, Siguero M, Fernandez-Teruel C, Cullell-Young M, Soto Matos-Pita A, Forster M | display-authors = 6 | title = Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study | journal = Annals of Oncology | volume = 28 | issue = 10 | pages = 2559–2566 | date = October 2017 | pmid = 28961837 | pmc = 5834091 | doi = 10.1093/annonc/mdx357 | name-list-style = vanc }}</ref><ref>{{cite press release | title=PharmaMar and Bionical Emas Launch Expanded Access Program for Lurbinectedin in Relapsed Small Cell Lung Cancer in the U.S. | publisher=Bionical Emas | via=PR Newswire | date=27 January 2020 | url=https://www.prnewswire.com/news-releases/pharmamar-and-bionical-emas-launch-expanded-access-program-for-lurbinectedin-in-relapsed-small-cell-lung-cancer-in-the-us-300993470.html | access-date=4 May 2022 | archive-date=18 August 2022 | archive-url=https://web.archive.org/web/20220818204932/https://www.prnewswire.com/news-releases/pharmamar-and-bionical-emas-launch-expanded-access-program-for-lurbinectedin-in-relapsed-small-cell-lung-cancer-in-the-us-300993470.html | url-status=live }}</ref>


Lurbinectedin is available in the U.S. under Expanded Access Program (EAP).<ref name=pmid28961837/><ref>{{cite journal |last1=Farago |first1=Anna F |last2=Drapkin |first2=Benjamin J |last3=Lopez-Vilarino de Ramos |first3=Jose Antonio |last4=Galmarini |first4=Carlos M |last5=Núñez |first5=Rafael |last6=Kahatt |first6=Carmen |last7=Paz-Ares |first7=Luis | display-authors=6 |title=ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line |journal=Future Oncology |date=January 2019 |volume=15 |issue=3 |pages=231–239 |doi=10.2217/fon-2018-0597 |pmid=30362375 |pmc=6331752 | name-list-style=vanc }}</ref>
Lurbinectedin is available in the U.S. under Expanded Access Program (EAP).<ref name=pmid28961837/><ref>{{cite journal | vauthors = Farago AF, Drapkin BJ, Lopez-Vilarino de Ramos JA, Galmarini CM, Núñez R, Kahatt C, Paz-Ares L | title = ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line | journal = Future Oncology | volume = 15 | issue = 3 | pages = 231–239 | date = January 2019 | pmid = 30362375 | pmc = 6331752 | doi = 10.2217/fon-2018-0597 | name-list-style = vanc }}</ref>


== References ==
== References ==

Revision as of 16:23, 27 August 2023

Lurbinectedin
Clinical data
Pronunciation/ˌlɜːrbɪˈnɛktɪdɪn/
LUR-bi-NEK-ti-din
Trade namesZepzelca
Other namesPM-01183
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa620049
License data
Pregnancy
category
Routes of
administration		Intravenous
Drug classAntineoplastic agent
ATC code
Legal status
Legal status
Identifiers
  • [(1R,2R,3R,11S,12S,14R,26R)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22-yl] acetate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC41H44N4O10S
Molar mass784.88 g·mol−1
3D model (JSmol)
  • CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O
  • InChI=1S/C41H44N4O10S/c1-17-11-20-12-25-39(48)45-26-14-52-40(49)41(38-22(9-10-42-41)23-13-21(50-5)7-8-24(23)43-38)15-56-37(31(45)30(44(25)4)27(20)32(47)33(17)51-6)29-28(26)36-35(53-16-54-36)18(2)34(29)55-19(3)46/h7-8,11,13,25-26,30-31,37,39,42-43,47-48H,9-10,12,14-16H2,1-6H3/t25-,26-,30+,31+,37+,39-,41+/m0/s1
  • Key:YDDMIZRDDREKEP-HWTBNCOESA-N

Lurbinectedin, sold under the brand name Zepzelca, is a medication used for the treatment of small cell lung cancer.[5][6][7]

The most common side effects include leukopenia, lymphopenia, fatigue, anemia, neutropenia, increased creatinine, increased alanine aminotransferase, increased glucose, thrombocytopenia, nausea, decreased appetite, musculoskeletal pain, decreased albumin, constipation, dyspnea, decreased sodium, increased aspartate aminotransferase, vomiting, cough, decreased magnesium and diarrhea.[5][6][7]

Lurbinectedin is a synthetic tetrahydropyrrolo [4,3,2-de]quinolin-8(1H)-one alkaloid analogue with potential antineoplastic activity.[8] Lurbinectedin covalently binds to residues lying in the minor groove of DNA, which may result in delayed progression through S phase, cell cycle arrest in the G2/M phase and cell death.[8]

Lurbinectedin was approved for medical use in the United States in June 2020.[9][5][6][7][10]

Medical uses

Lurbinectedin is indicated for the treatment of adults with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.[7]

Structure

Lurbinectedin is structurally similar to trabectedin, although the tetrahydroisoquinoline present in trabectedin is replaced with a tetrahydro β-carboline which enables lurbinectedin to exhibit increased antitumor activity compared with trabectedin.[11]

Synthesis

Synthesis of lurbinectedin starts from small, common starting materials that require twenty-six individual steps to produce the drug with overall yield of 1.6%.[12]

Mechanism of action

According to PharmaMar,[13] lurbinectedin inhibits the active transcription of the encoding genes. This has two consequences. It promotes tumor cell death and normalizes the tumor microenvironment. Active transcription is the process by which there are specific signal where information contained in the DNA sequence is transferred to an RNA molecule. This activity depends on the activity of an enzyme called RNA polymerase II. Lurbinectedin inhibits transcription through a very precise mechanism. Firstly, lurbinectedin binds to specific DNA sequences. It is at these precise spots that slides down the DNA to produce RNA polymerase II that is blocked and degraded by lurbinectedin. Lurbinectedin also has important role in tumor microenvironment. The tumor cells act upon macrophages to avoid them from behaving like an activator of the immune system. Macrophages can contribute to tumor growth and progression by promoting tumor cell proliferation and invasion, fostering tumor angiogenesis and suppressing antitumor immune cells.[14][15] Attracted to oxygen-starved (hypoxic) and necrotic tumor cells they promote chronic inflammation. So, not only that macrophages inhibit immune system avoiding the destruction of tumor cells, but they also create tumor tissue that allows tumor growth. However, macrophages associated with tumors are cells that are addicted to the transcription process. Lurbinectedin acts specifically on the macrophages associated with tumors in two ways: firstly, by inhibiting the transcription of macrophages that leads to cell death and secondly, inhibiting the production of tumor growth factors. In this way, lurbinectedin normalizes the tumor microenvironment.

History

Lurbinectedin was approved for medical use in the United States in June 2020.[9][5][6][7][10]

Efficacy was demonstrated in the PM1183-B-005-14 trial (Study B-005; NCT02454972), a multicenter open-label, multi-cohort study enrolling 105 participants with metastatic SCLC who had disease progression on or after platinum-based chemotherapy.[7][10] Participants received lurbinectedin 3.2 mg/m2 by intravenous infusion every 21 days until disease progression or unacceptable toxicity.[7] The trial was conducted at 26 sites in the United States, Great Britain, Belgium, France, Italy, Spain and Czech Republic.[10]

The U.S. Food and Drug Administration (FDA) granted the application for lurbinectedin priority review and orphan drug designations and granted the approval of Zepzelca to Pharma Mar S.A.[7][16]

Research

Clinical Trials

Lurbinectedin can be used as monotherapy in the treatment of SCLC.[medical citation needed] Lurbinectedin monotherapy demonstrated the following clinical results in relapsed extensive stage SCLC:

  • For sensitive disease (chemotherapy-free interval of ≥ 90 days) overall response rate (ORR) was 46.6% with 79.3% disease control rate and median overall survival (OS) being increased to 15.2 months.[17]
  • For resistant disease (chemotherapy-free interval of < 90 days) overall response rate (ORR) was 21.3% with 46.8% disease control rate and 5.1 months median overall survival (OS).[17]

Lurbinectedin is also being investigated in combination with doxorubicin as second-line therapy in a randomized Phase III trial.[medical citation needed] While overall survival in this trial is not yet known, response rates at second line were

  • 91.7% in sensitive disease with median progression-free survival of 5.8 months, and
  • 33.3% in resistant disease with median progression-free of 3.5 months.[18][19]

Lurbinectedin is available in the U.S. under Expanded Access Program (EAP).[18][20]

References

  1. ^ a b "Zepzelca". Therapeutic Goods Administration (TGA). 22 September 2021. Archived from the original on 30 September 2021. Retrieved 30 September 2021.
  2. ^ a b "AusPAR: lurbinectedin". Therapeutic Goods Administration (TGA). 4 May 2022. Archived from the original on 4 May 2022. Retrieved 4 May 2022.
  3. ^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Archived from the original on 3 April 2022. Retrieved 13 May 2022.
  4. ^ "Summary Basis of Decision (SBD) for Zepzelca". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
  5. ^ a b c d e "Zepzelca- lurbinectedin injection, powder, lyophilized, for solution". DailyMed. 15 June 2020. Archived from the original on 24 January 2021. Retrieved 24 September 2020.
  6. ^ a b c d "Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer" (Press release). Jazz Pharmaceuticals. 15 June 2020. Archived from the original on 15 June 2020. Retrieved 15 June 2020 – via PR Newswire.
  7. ^ a b c d e f g h "FDA grants accelerated approval to lurbinectedin for metastatic small". U.S. Food and Drug Administration (FDA). 15 June 2020. Archived from the original on 18 June 2020. Retrieved 16 June 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  8. ^ a b "Lurbinectedin". National Cancer Institute. Archived from the original on 16 May 2020. Retrieved 15 June 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  9. ^ a b "Zepzelca: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 19 October 2020. Retrieved 15 June 2020.
  10. ^ a b c d "Drug Trials Snapshots: Zepzelca". U.S. Food and Drug Administration (FDA). 15 June 2020. Archived from the original on 22 December 2020. Retrieved 28 June 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  11. ^ Takahashi R, Mabuchi S, Kawano M, Sasano T, Matsumoto Y, Kuroda H, et al. (March 2016). "Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary". PloS One. 11 (3): e0151050. Bibcode:2016PLoSO..1151050T. doi:10.1371/journal.pone.0151050. PMC 4795692. PMID 26986199.
  12. ^ He W, Zhang Z, Ma D (March 2019). "A Scalable Total Synthesis of the Antitumor Agents Et-743 and Lurbinectedin". Angewandte Chemie. 58 (12): 3972–3975. doi:10.1002/anie.201900035. PMID 30689274. S2CID 59306678.
  13. ^ PharmaMar presentation of Lurbinectedin's Mechanism of Action Lurbinectedin Mechanisim [sic] of Action | https://www.youtube.com/watch?v=8daELhxAXcQ Archived 18 November 2020 at the Wayback Machine
  14. ^ Qian BZ, Pollard JW (April 2010). "Macrophage diversity enhances tumor progression and metastasis". Cell. 141 (1): 39–51. doi:10.1016/j.cell.2010.03.014. PMC 4994190. PMID 20371344.
  15. ^ Engblom C, Pfirschke C, Pittet MJ (July 2016). "The role of myeloid cells in cancer therapies". Nature Reviews. Cancer. 16 (7): 447–462. doi:10.1038/nrc.2016.54. PMID 27339708. S2CID 21924175.
  16. ^ "Lurbinectedin Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). 1 August 2018. Archived from the original on 17 June 2020. Retrieved 16 June 2020.
  17. ^ a b Paz-Ares LG, Trigo Perez JM, Besse B, Moreno V, Lopez R, Sala MA, et al. (May 2019). "Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial". Journal of Clinical Oncology. 37 (15_suppl): 8506. doi:10.1200/JCO.2019.37.15_suppl.8506. S2CID 190884224.
  18. ^ a b Calvo E, Moreno V, Flynn M, Holgado E, Olmedo ME, Lopez Criado MP, et al. (October 2017). "Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study". Annals of Oncology. 28 (10): 2559–2566. doi:10.1093/annonc/mdx357. PMC 5834091. PMID 28961837.
  19. ^ "PharmaMar and Bionical Emas Launch Expanded Access Program for Lurbinectedin in Relapsed Small Cell Lung Cancer in the U.S." (Press release). Bionical Emas. 27 January 2020. Archived from the original on 18 August 2022. Retrieved 4 May 2022 – via PR Newswire.
  20. ^ Farago AF, Drapkin BJ, Lopez-Vilarino de Ramos JA, Galmarini CM, Núñez R, Kahatt C, Paz-Ares L (January 2019). "ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line". Future Oncology. 15 (3): 231–239. doi:10.2217/fon-2018-0597. PMC 6331752. PMID 30362375.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Lurbinectedin&oldid=1172518476"